Once-daily oral icotrokinra outperforms placebo in ulcerative colitis

For patients with moderately to severely progressive ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a objective effect astatine week 12 importantly much often than placebo, according to a survey published successful the Oct. 15 contented of the New England Journal of Medicine.